<DOC>
	<DOCNO>NCT01682161</DOCNO>
	<brief_summary>The purpose study evaluate change medication satisfaction measure Medication Satisfaction Questionnaire ( MSQ ) baseline endpoint patient switch paliperidone palmitate , either immediately delayed mode .</brief_summary>
	<brief_title>A Comparative Study Evaluate Evolution Medication Satisfaction Adherence Patients Unsatisfied With Current Oral Atypical Antipsychotics Switching Medication Paliperidone Palmitate</brief_title>
	<detailed_description>This prospective ( patient first identify follow forward time pass ) , multicenter ( study conduct multiple site ) , randomize ( study medication assign chance ) , comparative open-labeled ( people know identity intervention ) study . The study mainly consist 3 phase include , screen phase ( 14 day administration study medication ) , treatment phase , follow-up phase ( 28 day last dose study medication ) . In treatment phase , patient randomly assign equally 2 group ( Group 1 Group 2 ) , basis know unknown characteristic . Group 1 ( immediate switch group ) : Patients administer paliperidone palmitate immediately randomization continue throughout treatment phase . Group 2 ( delay switch group ) : Patients remain current oral antipsychotic Week 8 , later completely switch paliperidone palmitate . However , first 8 week symptoms satisfaction MSQ deteriorate Group 2 , may switch paliperidone palmitate earlier . Safety evaluation include evaluation adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination monitor throughout study . The total duration study approximately 148 day .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Meet diagnostic criterion schizophrenia accord Diagnostic Statistical Manual Mental Disorders Version IV Dissatisfied current medication ( Medication Satisfaction Questionnaire score less equal 4 ) clinician 's judgment may benefit switch medication Have receive oral antipsychotic least 4 week randomization Agrees protocoldefined use effective contraception History neuroleptic malignant syndrome Presence congenital prolongation QT interval History treatment depot antipsychotic , include longacting injectable risperidone paliperidone palmitate , within 90 day screen visit ; treatment clozapine within previous 60 day Any relevant medical history current presence systemic disease Significant risk suicidal , homicidal violent ideation behavior clinically assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>Invega Sustenna</keyword>
	<keyword>Antipsychotics</keyword>
	<keyword>Atypical antipsychotic</keyword>
	<keyword>Medication Satisfaction Adherence</keyword>
</DOC>